Dev

Dev

  • Joined: October 9, 2025
  • Articles: 6278

Thomas Rooney

Scientific Representative of Sanofi. Dr. Thomas Rooney is Head of Translational Research for Neurodegenerative Diseases in the Aging Therapeutic Strategic Unit at Sanofi.  Dr. Rooney received his BSc in Pharmacology from the University of Glasgow, UK (1984) and his PhD…

Eric Karran

Scientific Representative of Alzheimer Research UK. Dr Eric Karran is a molecular biochemist by training, with a particular interest in enzymology and proteinases.  He has spent most of his career in the pharmaceutical industry, leading and managing multi-disciplinary drug discovery…

Charles Scerri

Scientific Representative of Alzheimer Europe. Charles Scerri received his PhD degree in 2004 from the University of Dundee in Scotland where he studied the involvement of nicotinic acetylcholine receptors in Alzheimer’s disease. He is currently a senior academic and group…

Martin Rossor – Vice-Chair, SAB

In your opinion, what is the single biggest challenge for researchers investigating neurodegenerative disorders like Alzheimer’s or Parkinson’s? I feel that a big challenge if not the biggest challenge for researchers investigating neurodegenerative disorders is the difficulty of disease definition…

Eric Karran – SAB member – Alzheimer’s Research UK

Why do you think there has been so little progress, if any, in developing a drug that can slow the progression of neurodegenerative disorders? A major problem remains the preclinical to clinical translation. For some of the drugs that have…

Thomas Rooney – SAB member – Sanofi

In your opinion, what is the single biggest challenge for researchers investigating neurodegenerative disorders like Alzheimer’s and Parkinson’s? To identify the pathological mechanisms that are causally linked to the onset and progression of neurodegenerative disorders and to identify dynamic biomarkers…

Post
Filter